This seems like an extremely deceptive statement from Elysium. It is rife with suspicious ambiguity, since it purports to license a "pending patent" that they do not identify.
But I think worse than that, the headline describes an exclusive license of NR for anti-aging, which is not a right that the PTO is capable of granting, since Dartmouth already has a previous and superior right to use NR in an anti-aging formula. Dartmouth has a patent number that anyone can see and read -- 8,197,807 -- which means that Harvard and Mayo are excluded from licensing NR for anti-aging.
Here is the patent application that is probably referred to in the press release, which has the same inventors as mentioned in the press release:
What's really going on, I think, is that Harvard and Mayo are hoping to patent the use of a CD-38 inhibitor to enhance the effects of NR. That would be a special formulation of NR PLUS an enhancer. The NR would still have to be licensed from Dartmouth, but Elysium could, if they were able to legally sell NR, have exclusive access to the enhancer, were this patent ever granted. That patent may or may not be granted, and that method of using CD38 to improve the effectiveness of NR replenishment may or may not be safe or effective.
But if that is the patent they are talking about, then it is extremely deceptive to characterize that, as Elysium does, as an "Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging." That's not just false, it's blatantly and obviously false in a way that strongly suggests wrongful intent. The fact that they do not specify the patent application that they are excited about strengthens the likelihood of intent to deceive.
So the real question is why, now, is Elysium driven to such measures?
News 
Market Data 
Discover 
